Arrivent Biopharma News and Activities

Arrivent Biopharma is a company listed under the stock ticker AVBP (US).

Acquisition, funding and merger involving Arrivent Biopharma.

• Arrivent Biopharma has just announced a $100 Million fundraising (posted on January 10 2024).

View the org chart displaying its 23 main executives

Most searched biographies at Arrivent Biopharma

• Bing Yao, Chief Executive Officer and Director
• Merdad Parsey, Director
• James Healy, Director

Popular executive movements at Arrivent Biopharma

• Merdad Parsey has joined the company as Director  (posted on April 29 2025).

Create your alert
to follow the executive moves at Arrivent Biopharma.

Arrivent Biopharma has 2,340 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Biogen (United States (USA)).

Popular M&A news in Biotechnology

• Stylus Medicine has just announced a $85 Million fundraising (posted on May 16 2025).
• Azafaros has just announced a $132 Million fundraising (posted on May 15 2025).
• The new name of Garuda Therapeutics is Stratus Therapeutics. (posted on May 12 2025).

Popular contacts in Biotechnology

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships at WIRB-Copernicus Group
• Deepika Verma - Associate Director of Data Science and Digitalization at Wheeler Bio
• Steven Gillis - Chairman of the Board at VBI Vaccines

Learn more about the Biotechnology industry

Press releases by Arrivent Biopharma

• ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers | ArriVent Biopharma
• ArriVent BioPharma Reports Third Quarter 2024 Financial Results | ArriVent Biopharma
• News Releases | ArriVent Biopharma
• ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer | ArriVent Biopharma
• ArriVent BioPharma Reports Second Quarter 2024 Financial Results | ArriVent Biopharma
• ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer | ArriVent Biopharma
• ArriVent Appoints John Hohneker, M.D., to its Board of Directors | ArriVent Biopharma
• News Releases | ArriVent Biopharma
• News Releases | ArriVent Biopharma
• ArriVent Announces a Multi-Target ADC Collaboration with Alphamab | ArriVent Biopharma
• View more press releases Close

Social media about Arrivent Biopharma

• Arrivent Biopharma on Wikipedia, Google News & Yahoo Finance
• Arrivent Biopharma on LinkedIn, Twitter & YouTube